post

Scottish Medicines Consortium considers two new treatments for myeloma patients in Scotland

Patient advocacy news // 1st September 2020

Myeloma UK today took part in a meeting on whether to approve two new treatments for myeloma patients in Scotland.

The Scottish Medicines Consortium is considering whether lenalidomide (Revlimid®) maintenance treatment should be used following a stem cell transplant (HDT-SCT) in newly diagnosed patients. The committee also considered if carfilzomib (Kyprolis®), lenalidomide (Revlimid®) and dexamethasone should be used from patients who have received at least one prior therapy.

Patient Advocacy and Policy Officer, Daniel Cairns took part in the meeting via video conference.

Earlier in the summer Myeloma UK took part in the appraisals for both treatments with the National Institute for Healthcare Excellence (NICE).  NICE will announce the decision on approval for these treatments for use in the England, Wales and Northern Ireland in due course.

Lenalidomide maintenance was part of the largest myeloma clinical trial conducted in the UK, Myeloma XI and many UK patients will have received it treatment through this clinical trial.

In January, Myeloma UK conducted a Patient Treatment survey to capture patient experience and insight of lenalidomide maintenance. The survey received 466 responses, strengthening the case Myeloma UK was able to put forward for approval.

The new combination of carfilzomib (Kyprolis®), lenalidomide (Revlimid®) and dexamethasone was assessed in the phase III ASPIRE clinical trial showing promising results for patients with relapsed myeloma.

Patient Advocacy and Policy Officer Daniel Cairns

“I am pleased that the work of SMC has restarted after being postponed due to the COVID-19 pandemic. It is encouraging that two new treatments have been considered for patients with myeloma in Scotland.

We now have compelling data showing the benefits of both treatments for patients with myeloma, and we will be doing everything to ensure that they are recommended for use within NHS Scotland.

I want to thank all of the patients who took part in our survey on lenalidomide (Revlimid®) maintenance and the patients who provided positive comments for the carfilzomib (Kyprolis®) combination.”

Lenalidomide (Revlimid®), produced by the pharmaceutical company Celgene, is an immunomodulatory drug which works by affecting the body’s immune system. It is currently approved either as a single or combination treatment at further points in the myeloma pathway. You can read more about this treatment in our lenalidomide (Revlimid®) treatment guide.

Carfilzomib (Kyprolis®), produced by the pharmaceutical company Amgen, is a proteasome inhibitor drug used in the treatment of myeloma. It is also approved at further points in the myeloma pathway. You can read more about this treatment in our carfilzomib (Kyprolis®) treatment guide.

The SMC will announce its decision on whether or not to approve these treatments for patients with myeloma in Scotland at the start of October.

A decision on whether the treatment will be made available to patients in England, Wales will be published in due course. Northern Ireland typically follow NICE decisions. NICE may want to meet again to discuss the appraisal at it is not possible to give a precise timescale for the decision at the moment.

Further information

If you have any questions or comments on the decision, please email policy@myeloma.org.uk or call the Myeloma Infoline on 0800 980 3332 during office hours, Monday to Friday.